Product name: Transform — Paragon Pharmatech
Strength per capsule: 500 mcg Tesofensine + 500 mcg SLU‑PP‑332
Capsules per bottle: 60 vegetarian capsules

Other names:
Tesofensine: NS‑2330; triple monoamine reuptake inhibitor
SLU‑PP‑332: ERR agonist; estrogen‑related receptor agonist; exercise‑mimetic small molecule

CAS numbers:
Tesofensine: 195875‑84‑4
SLU‑PP‑332: 303760‑60‑3

Chemical structure (summary):
Tesofensine is a bicyclic tetrahydroisoquinoline‑derived compound containing aromatic phenyl substituents and a tertiary amine, enabling blood–brain barrier penetration and interaction with monoamine transporters.
SLU‑PP‑332 is a synthetic heterocyclic small molecule containing fused aromatic and nitrogen‑containing ring systems designed to bind and activate estrogen‑related receptors (ERRα/ERRγ), nuclear transcription factors involved in mitochondrial metabolism and oxidative phosphorylation.

10 Strong Points & Benefits 

1. Tesofensine has demonstrated clinically significant weight reduction in randomized controlled trials, with meaningful improvements in metabolic risk markers.

2. Tesofensine reduces caloric intake through central appetite regulation while also increasing metabolic expenditure via sympathetic activation.

3. SLU‑PP‑332 activates ERR pathways that regulate mitochondrial biogenesis, oxidative metabolism, and endurance‑related gene expression.

4. ERR activation enhances fatty‑acid oxidation and glucose utilization in skeletal muscle and liver in experimental models.

5. The combination provides complementary mechanisms: central appetite modulation and peripheral metabolic activation.

6. Both compounds influence mitochondrial function and cellular bioenergetics, which are central to metabolic disease research.

7. Tesofensine pharmacokinetics and safety have been characterized in controlled human trials.

8. SLU‑PP‑332 produces transcriptional changes resembling endurance training adaptations in preclinical research.

9. Combination strategies targeting multiple metabolic pathways are increasingly recognized as more effective than single‑mechanism interventions in metabolic research.

10. Both compounds are chemically stable and suitable for precise analytical verification using HPLC and LC‑MS, supporting reproducible research outcomes.

Overview

Transform is a research formulation combining Tesofensine, a centrally acting monoamine reuptake inhibitor investigated for obesity and metabolic disorders, with SLU‑PP‑332, a selective activator of estrogen‑related receptors involved in mitochondrial biogenesis and oxidative metabolism.

Tesofensine was initially investigated in neurological research before its metabolic effects were recognized. By inhibiting dopamine, norepinephrine, and serotonin reuptake, Tesofensine enhances satiety signaling and reduces caloric intake while also influencing thermogenesis and energy expenditure.

SLU‑PP‑332 represents a newer class of metabolic modulators that act through nuclear receptor signaling rather than direct receptor agonism in the central nervous system. Estrogen‑related receptors regulate genes controlling mitochondrial respiration, oxidative phosphorylation, and lipid metabolism. Activation of these pathways produces metabolic adaptations similar to endurance training in experimental systems.

The rationale for combining these compounds is based on targeting multiple components of energy balance simultaneously: food intake, metabolic efficiency, mitochondrial function, and substrate utilization. Such multimodal strategies are an emerging theme in metabolic and obesity research.

Paragon Pharmatech manufactures Transform capsules under controlled, GMP‑aligned conditions with identity, purity, and potency testing to ensure reproducibility in laboratory and scientific applications.

How It Works (Mechanisms & Pharmacology)

Tesofensine Mechanism of Action

Tesofensine acts primarily as a triple monoamine reuptake inhibitor, blocking dopamine, norepinephrine, and serotonin transporters. This leads to increased synaptic concentrations of these neurotransmitters in brain regions involved in appetite regulation, reward processing, and satiety.

Enhanced norepinephrine signaling increases sympathetic nervous system activity, contributing to increased thermogenesis and lipolysis. Dopamine signaling influences reward‑driven feeding behavior, reducing compulsive eating patterns in experimental settings. Serotonin contributes to satiety signaling and appetite suppression.

Pharmacokinetic studies show Tesofensine has a relatively long elimination half‑life and active metabolites, resulting in sustained pharmacodynamic effects. Brain imaging studies demonstrate modulation of neural activity in hypothalamic and limbic regions involved in feeding behavior.

SLU‑PP‑332 Mechanism of Action

SLU‑PP‑332 activates estrogen‑related receptors, particularly ERRα and ERRγ. These nuclear receptors regulate transcription of genes involved in mitochondrial respiration, oxidative phosphorylation, fatty‑acid oxidation, and endurance metabolism.

Activation of ERR pathways increases expression of PGC‑1α and downstream regulators of mitochondrial biogenesis. Experimental studies demonstrate increased oxygen consumption, improved endurance capacity, and enhanced metabolic flexibility in animal models.

ERR activation also influences glucose uptake, skeletal muscle fiber composition, and lipid utilization. These effects support improved metabolic efficiency and resilience in models of metabolic stress.

Combined Mechanistic Model

The combined formulation integrates complementary mechanisms:

• Reduced caloric intake through central appetite regulation

• Increased mitochondrial capacity and oxidative metabolism

• Enhanced fatty‑acid oxidation and glucose handling

• Improved metabolic flexibility and energy balance

This multi‑pathway approach reflects current scientific understanding that metabolic diseases involve multiple interconnected systems including central nervous regulation, mitochondrial function, and endocrine signaling.

What Studies Have Shown 

Tesofensine Clinical Studies

Randomized controlled trials in overweight and obese subjects demonstrated significant weight reduction compared with placebo. In several studies, subjects receiving Tesofensine experienced weight reductions in the range of approximately 5–12% over periods of several months, accompanied by reductions in waist circumference and improvements in lipid and glycemic markers.

Clinical trials also documented reductions in caloric intake and increased satiety scores in controlled feeding environments. Neuroimaging research showed changes in brain regions associated with appetite regulation and reward processing, supporting the mechanistic basis for reduced food intake.

Adverse effects reported in clinical studies included dry mouth, insomnia, and mild increases in heart rate. Cardiovascular monitoring was incorporated into protocols to evaluate potential sympathomimetic effects.

SLU‑PP‑332 Preclinical Studies

Experimental studies in rodents demonstrated increased endurance capacity, enhanced mitochondrial respiration, and upregulation of genes associated with oxidative metabolism following administration of SLU‑PP‑332.

In models of diet‑induced obesity, treatment resulted in reductions in adiposity and improvements in glucose tolerance and insulin sensitivity. Tissue analysis revealed increased mitochondrial density and oxidative enzyme activity in skeletal muscle.

Gene expression analyses confirmed activation of pathways regulating fatty‑acid oxidation, mitochondrial respiration, and energy metabolism, consistent with exercise‑like adaptations.

Mechanistic and Translational Research

Research into estrogen‑related receptors has established their role in metabolic regulation, mitochondrial function, and endurance physiology. Activation of these pathways produces systemic metabolic changes that parallel adaptations seen in aerobic training.

Tesofensine research has demonstrated consistent central appetite‑modulating effects, making it one of the most potent investigational anti‑obesity agents studied in controlled trials.

Combination Rationale

Although direct clinical trials of this exact combination are limited, scientific literature supports the concept that combining agents that reduce caloric intake with those that increase metabolic capacity may produce complementary effects on energy balance and body composition.

Evidence synthesis therefore indicates strong clinical evidence for Tesofensine, strong mechanistic and preclinical evidence for SLU‑PP‑332, and a scientifically plausible rationale for combination approaches targeting multiple metabolic pathways.

Usage & Quality Compliance 

Transform capsules are manufactured under GMP‑aligned conditions. Each batch undergoes:

• Identity testing by HPLC or LC‑MS

• Potency assay for both active ingredients

• Residual solvent testing

• Heavy metal analysis

• Microbiological testing

• Stability testing

Research protocols may include monitoring of body weight, metabolic panels, lipid profiles, glucose tolerance, cardiovascular parameters, and mitochondrial biomarkers where relevant.

Randomized, double‑blind, placebo‑controlled designs are recommended to minimize bias and improve reproducibility in metabolic research.

Safety Note

Tesofensine may produce sympathomimetic effects including increased heart rate, insomnia, dry mouth, and mild increases in blood pressure. Cardiovascular monitoring is recommended in experimental settings.

SLU‑PP‑332 remains investigational, and long‑term human safety data are limited. Nuclear receptor modulation may influence multiple metabolic pathways, requiring careful dosing and monitoring in research protocols.

Contraindications for experimental protocols may include significant cardiovascular disease, uncontrolled hypertension, severe metabolic disorders, or concurrent investigational metabolic agents.

Full Reference List 

Astrup A et al. Tesofensine in the treatment of obesity: randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/20300078/

Hjorth S et al. Tesofensine pharmacology and monoamine reuptake inhibition. https://pubmed.ncbi.nlm.nih.gov/17591541/

Billon C, Auwerx J. Nuclear receptors and mitochondrial function in metabolic disease. https://pubmed.ncbi.nlm.nih.gov/22498809/

Rangwala SM, Wang X. Estrogen‑related receptors and energy metabolism. https://pubmed.ncbi.nlm.nih.gov/18713868/

Zhang Y et al. ERR agonists and exercise‑mimetic metabolic effects. https://pubmed.ncbi.nlm.nih.gov/37651246/

PGC‑1α and mitochondrial biogenesis review. https://pubmed.ncbi.nlm.nih.gov/15254340/

© Paragon Pharmatech — Educational Material 2025. For scientific and educational purposes only.

Remember, this product is intended for research purposes only and should not be used for human consumption without proper medical guidance. As with any supplement, it is important to prioritize your health and safety, and to consult with a healthcare professional if you have any underlying health concerns before incorporating this product into your routine.
This product is not a food product. By acquiring this product, you are in full knowledge that it’s not a food, nor is it for human consumption and it’s for market research purposes only